Achieving Optimized Viral Clearance with Comprehensive Support and Expertise

Early-stage viral clearance (VC) is a foundational element of biopharmaceutical development for mammalian cell–derived products. VC is not a rapid, single-step activity but a multi-phase program involving process development, risk assessment, and rigorous, unit-operation–specific testing—often requiring multiple runs and troubleshooting. FUJIFILM Biotechnologies’ VC model integrates early feasibility studies, small-scale spiking experiments, and evaluation of inactivation, chromatography, and filtration steps to de-risk processes and inform later development. Collaboration with spiking houses and the application of advanced analytics, such as next-generation sequencing (NGS) and quantitative PCR (qPCR), enhance understanding of viral load and clearance performance. Through proactive planning, expert data interpretation, and regulatory foresight, the approach positions early VC not merely as a compliance requirement but as a strategic lever to optimize purification strategies, maintain predictable timelines, and enable smooth progression from early clinical stages to commercialization while safeguarding product viral safety. Download the insight brief to learn more.